Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

959
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
959
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

875
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
875
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

865
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
865
Two-Compartment Open Model: IV Bolus Administration01:18

Two-Compartment Open Model: IV Bolus Administration

1.3K
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
1.3K
Three-Compartment Open Model01:06

Three-Compartment Open Model

1.0K
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression and hippocampal subfield volume in older adults.

Translational psychiatry·2026
Same author

Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Programmes that Integrate Parenting Support and Financial Well-Being Support: A Systematic Scoping Review.

Journal of prevention (2022)·2026
Same author

Alcohol use and <i>APOE ε</i>4 interaction with cognitive domains among American adults from diverse racial/ethnic groups: A HABS-HD study.

Alzheimer's & dementia. Behavior & socioeconomics of aging·2026
Same author

Tackling the complexity of cancer with generative models.

Cell·2026
Same author

The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Mar 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Implementing a pharmacist consultation model for multimodal insulin therapy.

Angela Hodges1, James Hall2, Esther Castellanos2

  • 1Texas Health Huguley Hospital Fort Worth South, Burleson, TX. angela.hodges@ahss.org.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|April 26, 2017
PubMed
Summary

Pharmacist-managed insulin dosing using a multimodal insulin protocol (MMIP) effectively controlled hyperglycemia in hospitalized patients. The study achieved target blood glucose levels within three months of implementation.

Keywords:
basal–bolus insulin therapydiabetes mellitushyperglycemiainpatientinsulinprotocol

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Area of Science:

  • Hospital Pharmacy Practice
  • Endocrinology
  • Quality Improvement Initiatives

Background:

  • Hyperglycemia is associated with adverse outcomes including thrombosis, impaired wound healing, and reduced immune response.
  • Current guidelines recommend multimodal (basal-bolus) insulin therapy for non-critically ill inpatients.
  • Effective glycemic management is crucial for improving patient outcomes in hospital settings.

Purpose of the Study:

  • To describe the implementation of pharmacist-managed insulin dosing for hospitalized patients.
  • To evaluate the effectiveness of a multimodal insulin protocol (MMIP) managed by pharmacists.
  • To improve glycemic control in selected hyperglycemic inpatients.

Main Methods:

  • A multimodal insulin protocol (MMIP) was developed targeting patients with blood glucose (BG) >180 mg/dL.
  • Pharmacists provided protocol-directed insulin dosing, including patient assessment and insulin adjustments.
  • Electronic notifications and computerized prescriber order entry facilitated pharmacist interventions.

Main Results:

  • 158 hyperglycemic patients received pharmacist-managed insulin dosing over a 90-day period.
  • The mean BG concentration goal of ≤180 mg/dL by day 3 was achieved in the second and third months post-implementation.
  • The pharmacist-led MMIP demonstrated successful glycemic control in a hospital setting.

Conclusions:

  • Pharmacist-managed insulin dosing under an MMIP is a viable strategy for improving glycemic control in hospitalized patients.
  • The MMIP implementation led to the successful attainment of target blood glucose levels.
  • This approach represents a valuable quality improvement in hospital diabetes management.